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The gene mutated in the human genetic disorder atax-
ia-telangiectasia codes for a protein, ATM, the known
functions of which include response to DNA damage,
cell cycle control, and meiotic recombination. Consist-
ent with these functions, ATM is predominantly present
in the nucleus of proliferating cells; however, a signifi-
cant proportion of the protein has also been detected
outside the nucleus in cytoplasmic vesicles. To under-
stand the possible role of extra-nuclear ATM, we ini-
tially investigated the nature of these vesicles. In this
report we demonstrate that a portion of ATM co-local-
izes with catalase, that ATM is present in purified mouse
peroxisomes, and that there are reduced levels of ATM
in the post-mitochondrial membrane fraction of cells
from a patient with a peroxisome biogenesis disorder.
Furthermore the use of the yeast two-hybrid system
demonstrated that ATM interacts directly with a protein
involved in the import of proteins into the peroxisome
matrix. Because peroxisomes are major sites of oxida-
tive metabolism, we investigated catalase activity and
lipid hydroperoxide levels in normal and A-T fibro-
blasts. Significantly decreased catalase activity and in-
creased lipid peroxidation was observed in several A-T
cell lines. The localization of ATM to peroxisomes may
contribute to the pleiotropic nature of A-T.
Ataxia-telangiectasia (A-T)1 is a rare human autosomal re-
cessive multisystem disease that is characterized by a wide
range of features including, progressive cerebellar ataxia with
onset during infancy, occulocutaneous telangiectasia, suscepti-
bility to bronchopulmonary disease and neoplasia, occulomotor
disturbances, progeric hair and skin changes, clinical and cel-
lular sensitivity to ionizing radiation, chromosomal instability,
and growth and developmental abnormalities (1, 2). The gene
mutated in A-T (ATM for ataxia-telangiectasia mutated) was
cloned and shown to code for a protein of 350 kDa belonging to
the phosphatidylinositol 3-kinase family (3). Within this fam-
ily, ATM is most closely related to a group of proteins involved
in maintaining the integrity of DNA and/or cell cycle control in
response to DNA damage. These include mammalian DNA-de-
pendent protein kinase (DNA-PK), Tel1p, and MEC1p from
Saccharomyces cerevisiae, Rad3p, from Saccharomyces pombe,
and MEI-41 from Drosophila melanogaster (4, 5). Like DNA-
PK, ATM does not appear to be a lipid kinase but rather
functions as a serine/threonine protein kinase (6, 7). ATM has
been implicated in several signaling pathways including DNA
damage recognition (2), radiation signal transduction and cell
cycle control (8–12), and meiotic recombination (13–15). There
is also evidence that ATM plays a more general intracellular
signaling role (16–19). Further support for the importance of
ATM has been provided by the complementation of radiosensi-
tivity and cell cycle defects in A-T cells by full-length ATM
cDNA (20, 21).
Several groups, including our own, have shown that ATM is
predominantly a nuclear protein, although a significant
amount is present outside the nucleus (13, 22–25). Many of the
features of A-T, such as aberrant meiosis and cell cycle check-
point control, are consistent with the nuclear localization of
ATM. However, the neurological symptoms are difficult to ex-
plain in terms of defective DNA damage response. Using im-
munoelectron microscopy we showed labeling of ATM antibod-
ies in cytoplasmic vesicles of varying sizes (60–230 nm) in both
fibroblasts and lymphoblastoid cells (24). The heterogeneous
size of the vesicles labeled with ATM antibodies and the punc-
tate immunofluorescence was suggestive of peroxisomes (24).
Peroxisomes are single membrane-bound organelles present in
virtually all eukaryotic cells. They contain a range of enzymes
involved in a variety of metabolic processes including peroxide-
based respiration, oxidation of very long chain fatty acids, and
synthesis of plasmalogens and bile acids. The majority of per-
oxisomal matrix proteins are imported into the peroxisome via
a noncleavable peroxisomal targeting signal type 1 (PTS1),
which consists of a tripeptide SKL or conserved variant at the
extreme C terminus (26). In this report we show that ATM
co-localizes with the peroxisomal matrix protein catalase and
binds the PTS1 receptor. The presence of ATM in peroxisomes
may provide an explanation for some of the pleiotropic symp-
toms of A-T.
EXPERIMENTAL PROCEDURES
Materials—Antibody to human catalase (prepared in sheep) was
purchased from Biodesign International (Kennebunk, ME). The second-
ary antibodies used were rhodamine anti-sheep Ig and fluorescein anti-
rabbit Ig (both prepared in donkey and suitable for double labeling;
Chemicon International Inc., Tennecula, CA). Horseradish peroxidase-
conjugated goat anti-rabbit IgG and fluorescein isothiocyanate- and
horseradish peroxidase-conjugated rabbit anti-mouse Ig were obtained
from Silenus. Keyhole limpet hemocyanin and m-maleimidobenzoyl-N-
hydroxysuccinimide ester were obtained from Sigma. Nycodenz was
obtained from Nycomed AS (Oslo, Norway). Adult female mice (Quack-
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enbush strain) were obtained from the Central Animal Breeding House
(Pinjarra Hills, Brisbane, Australia). ATM knockout mice were bred
from heterozygotes kindly provided by Dr. Phil Leder (Harvard Medical
School, Boston, MA). The lipid peroxidation kit was from Cayman
Chemicals (Ann Arbor, MI).
Cell Culture—Primary human fibroblasts and neonatal foreskin fi-
broblasts were obtained from Prof. Kay Ellem of this institute and
cultured in RPMI medium containing 10% fetal calf serum. Zellweger
fibroblasts from complementation group 4 (GM13267) were obtained
from the Human Genetic Mutant Cell Repository, Coriell Laboratories.
GM 3487A, GM 3984A, and GM 3395 are nontransformed A-T fibro-
blasts, and AT5B/VA and AT13LA SV are SV40 transformed A-T fibro-
blasts that were obtained from Dr. R. Reddel (Westmead Hospital,
Sydney, Australia).
Preparation of Antibodies—The ATM4BA antibody has been de-
scribed previously (24). A mouse monoclonal antibody (CT1) to the
extreme C-terminal sequence of ATM (DPKNLSRLFPGWKAWV) was
prepared by standard methods. A peptide with this sequence was syn-
thesized by Chiron Mimotopes with an N-terminal cysteine residue to
facilitate coupling to keyhole limpet hemocyanin using m-maleimido-
benzoyl-N-hydroxysuccinimide ester as described (24). The conjugate
was used to immunize BALB/c mice. Spleen cells from these mice were
fused with the Sp2/O myeloma cell line. Positive hybridomas were
detected by enzyme-linked immunosorbent assay with unconjugated
peptide bound to plates (24). The CT-1 monoclonal antibody is of the
IgG1 isotype and recognizes both human and murine ATM.
Fluorescence Immunohistochemistry—For immunofluorescence stud-
ies, cells grown on coverslips, were fixed with 4% formaldehyde in PBS
for 20 min and then permeabilized with PBS containing 0.3% Triton
X-100 for 5 min. Coverslips were incubated with primary antibody in
PBS containing 2% fetal calf serum at 4 °C overnight, washed three
times in PBS containing 0.05% Tween 20, and then incubated with
secondary antibody for 3 h at room temperature. The antibodies were
used at the following dilutions: ATM-4BA (1:200); CT-1 culture super-
natant (undiluted); CT-1 ascites fluid (1:200); and anti-catalase (1:200).
Coverslips were mounted using Vectashield fluorescence mounting me-
dium (Vector Labs) and viewed with a Bio-Rad MRC500 confocal mi-
croscope using K1/K2 filters.
Yeast Two-hybrid Analysis—A partial catalase clone (309301) was
obtained from the IMAGE Consortium cDNA clone library (Genome
Systems Inc.). A 1.4-kb nearly full-length EcoRI-NotI catalase fragment
was subcloned into the EcoRI/NotI sites of pSL1180. The remaining 59
end was subcloned by isolating a 280-bp EcoRI fragment from pCAT 2.2
(a gift from Dr. Nick Hayward of this institute) and inserting it into the
EcoRI site of pSL-CAT1.4. Clones were screened for correct orientation
of the 280-bp fragment. pSL1180 containing full-length catalase was
designated pSL-catalase. Catalase was then subcloned into pGBT9 by
polymerase chain reaction. The sense oligonucleotide 59-GGAAGATC-
TCCATGGCTGACAGCCGGG-39, which encodes a BglII restriction
site, and the antisense oligonucleotide 59-ACTGCATGCATCAGATTT-
GCCTTCTCCCTTGC-39, which encodes an NsiI restriction site, were
used in a polymerase chain reaction using Pfu DNA polymerase with
pSL-catalase as the template. The polymerase chain reaction product
was purified and digested with BglII and NsiI and cloned into pGBT9
digested with BamHI and PstI. The sequence integrity of catalase was
confirmed by DNA sequencing.
The pGAD10 plasmid containing a cDNA insert for Pex5p was kindly
provided by Dr. S. Gould (27). The plasmid ATM 4.01 was obtained by
cloning the NsiI/AseI fragment of full-length ATM cDNA into the yeast
DNA-binding domain vector pAS2. This fragment contains the C-ter-
minal of ATM corresponding to amino acid residues 1666–3056 plus
some untranslated 39 sequence (12). To remove 491 bp from the 39-end
of ATM 4.01, the plasmid was digested with NcoI (restriction site at
8964 bp) and NotI (site in vector). The linearized plasmid (3.51 kb) was
religated, and purified after transformation. An 8.7-kb ATM fragment
(corresponding to amino acid residues 1- 2934) was cloned into the NcoI
site of pAS2-1 (12).
The Matchmaker two-hybrid system from CLONTECH (Palo Alto,
CA) was used in which the combination of genetic selection for histidine
prototrophy and the assay for b-galactosidase activity is applied to
identify positive clones. Growth, maintenance, and transformation of S.
cerevisiae were carried out according to the CLONTECH Matchmaker
two-hybrid system protocol using 25 mM 3-aminotriazole to eliminate
many of the false positives that can occur. The S. cerevisiae strain
Y190 (MATa, ura 3-52, his3-200, lys2-801, ade 2-101, trp1-901,
leu2-3, 112, gal 4D, gal 80D, Cyh r2, URA3::GAL1UAS-GAL1TATALacZ,
LYS2::GAL1UAS-HIS3TATA-HIS3) was used, and it expresses the re-
porter genes lacZ (E. coli) and HIS3 (S. cerevisiae) under the control of
the GAL1 promoter.
Subcellular Fractionation and Western Blotting—Two 150-cm2 flasks
each of neonatal foreskin and GM13267 fibroblasts were trypsinized to
remove the cells from the culture dish, and the cells were suspended in
2 ml/flask of ice-cold homogenization buffer. The procedures for prepa-
ration of nuclear and post-mitochondrial pellet fractions and Western
blotting for ATM were as described previously (24).
Purification of Mouse Liver Peroxisomes—Mouse livers were excised,
and each was immediately suspended in 7.5 ml of cold sucrose/ethanol
solution (0.25 M sucrose and 0.1% ethanol, containing 18 ml 0.1 M
phenylmethylsulfonyl fluoride, 20 ml 10 mg/ml leupeptin, 20 ml of 10
mg/ml aprotinin). The livers were minced finely using a McIlwain tissue
chopper followed by homogenization on ice with one stroke of a Potter/
Elvehjem homogenizer. The homogenate was centrifuged at 1,000 3 g
for 10 min at 4 °C, and the supernatant was transferred to a fresh tube
and centrifuged at 2,800 3 g for 15 min. The supernatant from this step
was centrifuged at 16,000 3 g for 10 min to obtain an organelle pellet.
This was suspended in 5 ml of sucrose/ethanol and again centrifuged at
16,000 3 g for 10 min at 4 °C. The resulting washed organelle pellet was
resuspended in 0.5 ml of sucrose/ethanol solution and loaded onto a
Nycodenz (Nycomed AS) gradient (15–40%, in STE (0.25 M sucrose
containing 10 mM Tris-HCl, pH 7.4, 0.1 mM EDTA)) and centrifuged for
40 min at 80,000 3 g using a VTi65.1 rotor (Beckman). Fractions (0.5
ml) were collected and assayed for catalase, succinate dehydrogenase
activity, density (refractometry), and protein concentration by standard
methods.
For Western blotting, proteins were separated by SDS-polyacryl-
amide gel electrophoresis on 4% gels in a Protean II apparatus (Bio-
Rad), transferred to Hybond C nitrocellulose membrane (Amersham
Pharmacia Biotech) at 100V for 1 h, and then blocked for 2 h at room
temperature in 5% blotto (5% nonfat milk powder in PBS). The mem-
branes were then incubated with CT-1 antibody (culture supernatant
diluted 1:10) overnight at 4 °C. This was followed by five washes in PBS
containing 0.05% Tween 20 for 5 min and then a 1-h incubation with
horseradish peroxidase-conjugated anti-rabbit IgG at room tempera-
ture. The membranes were again subjected to repeated washing as
before and developed using the Renaissance chemiluminescence system
(Dupont).
Lipid Peroxidation Measurements—Determination of lipid peroxides
was performed on cell homogenates of normal and A-T fibroblasts using
the lipid hydroperoxide kit from Cayman Chemicals according to the
manufacturer’s instructions.
Catalase Assays—Fibroblasts were grown in 75-cm2 flasks to 70%
confluency. The cells were washed twice in PBS and scraped off the
plastic, and the pellet resuspended in 400 ml of ice-cold 10 mM Tris-HCl,
pH 7.0, containing 0.1 mg/ml digitonin and 0.25 M sucrose. After incu-
FIG. 1. The C terminus of ATM. A, comparison of the extreme
C-terminal sequences of ATM and two peroxisomal enzymes, catalase
and copper zinc-superoxide dismutase. B, Western blot of cerebellar
extracts from wild type (lanes 1 and 2) and atm2/2 mice (lanes 3 and 4)
using CT-1 monoclonal antibody specific for ATM. DNA-PK was used as
a loading control.
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bation on ice for 10 min, Triton X-100 was added to a final concentration
of 0.1%. Following a further 5-min incubation on ice, the mixture was
vortexed and used for assay of catalase activity as measured by the
decrease in absorbance of hydrogen peroxide at 240 nm (28).
RESULTS
The C Terminus of ATM Is Similar to That of Catalase—The
heterogeneous size of the vesicles labeled with ATM antibodies,
the presence of a defined single membranous structure, and the
punctate immunofluorescence, which we observed previously
was suggestive of peroxisomes (24). Peroxisomes are single-
membrane-bound organelles present in virtually all eukaryotic
cells, and they contain a range of enzymes involved in a variety
of metabolic processes including peroxide-based respiration,
oxidation of very long chain fatty acids, and synthesis of plas-
malogens and bile acids. Furthermore, comparison of the C-
terminal sequences of the peroxisomal matrix enzyme catalase,
which contains sequence important for its localization to this
organelle, with that of ATM revealed some sequence conserva-
tion (Fig. 1A). This relatedness is evident in two regions as
indicated by bold type in Fig. 1A. It is noteworthy that the
C-terminal sequence (last 16 amino acids) shows 100% conser-
vation between mouse and human ATM. A monoclonal anti-
body (CT-1) was raised against the extreme C-terminal 16
amino acids. The specificity of the CT-1 antibody was deter-
mined by immunoblotting with tissue extracts from normal and
atm2/2 mice (Fig. 1B).
Colocalization of ATM and Catalase—To confirm the local-
ization of ATM to peroxisomes, we performed double-labeling
experiments using an antibody to human catalase and two
different antibodies to ATM, the polyclonal antibody ATM-4BA
as described previously (24) and the monoclonal antibody (CT-
1). When catalase was stained using a rhodamine-labeled sec-
ondary antibody (red) and ATM with a fluorescein isothiocya-
nate-labeled secondary antibody (green), it is evident that co-
localization (yellow staining) occurs (Fig. 2A), demonstrating
that ATM is localized to peroxisomes. However, it is also clear
that ATM is present in other cytoplasmic vesicles not stained
with anti-catalase. This is consistent with the report of Lim et
al. (29), which shows that ATM binds to b-adaptin and b-neu-
ronal adaptin-like protein, components of clathrin-coated and
secretory vesicles. Confocal microscopy was used to confirm the
co-localization of catalase and ATM using the CT-1 antibody
(Fig. 2B).
ATM Is Present in Purified Peroxisomes—Because peroxi-
somes are readily purified from mouse liver using Nycodenz
gradients, we used this approach to further demonstrate that
ATM is present in peroxisomes. The results of such a gradient
analysis appear in Fig. 3A, demonstrating that catalase activ-
ity peaks in fraction 3. Small amounts of mitochondria are also
present elsewhere on the gradient as evidenced by the presence
of succinate dehydrogenase peaking in fraction 6. Fractions
were run on a SDS gel and checked for the presence of ATM by
immunoblotting with CT-1 antibody. It can be seen that ATM is
detected in the peak fraction (#3) from the gradient, coinciding
with the peak of catalase (Fig. 3B). It is evident that the
recovery of ATM in these fractionated peroxisomes is low, but
this protein was reproducibly observed to coincide with the
catalase peak. This is also not due to nuclear contamination
because the much more highly abundant protein DNA-depend-
FIG. 2. Co-localization of ATM and catalase by immunohistochemistry. A, double-label confocal immunofluorescence histochemistry of
normal fibroblasts showing staining of catalase (red) and ATM with ATM4BA antibody (green). The merged image shows co-localization of ATM
and catalase in yellow. Bar, 10 mm. B, double-label immunofluorescence confocal microscopy of normal fibroblasts using the monoclonal antibody
CT-1 (a) and anti-catalase (b) antibodies. The images were collected on a Bio-Rad MRC500 confocal microscope using K1/K2 filters.
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ent protein kinase (DNA-PK) was not detected in any of the
gradient fractions (Fig. 3B, lower panel).
ATM Binds to the Peroxisomal PTS1 Receptor—The C-ter-
minal sequence similarity of ATM to catalase suggested that
ATM might be imported into peroxisomes in a manner analo-
gous to catalase. The import of proteins into peroxisomes re-
quires a host of peroxisome assembly factors or peroxins that
include specific PTS receptors, which recognize the targeting
signals (30). In the case of catalase the PTS1 signal was
thought to be the SHL sequence (positions 11–9 from the C
terminus), which is in the corresponding position to a related
sequence in ATM, SRL (Fig. 1A). More recently it has been
shown that the extreme C-terminal sequence KANL is suffi-
cient to target catalase to the peroxisome (31, 32). The C-
terminal sequence of ATM is KAWV; however, it is not yet
known whether this constitutes a PTS1 signal. Recognition of
the PTS1 signal is mediated by the PTS1 receptor, now known
as Pex5p (30). In our study the yeast two-hybrid assay was
used to show that Pex5p binds to ATM. A 4.01-kb construct
corresponding to the C-terminal half of ATM was cloned into
the yeast vector pAS2, which contains the GAL4 DNA-binding
domain (12, 24). Pex5p cloned into the pGAD10 vector was used
to co-transform yeast cells, and interaction between the two
proteins was assayed using a liquid culture b-galactosidase
assay. As a control, the coding sequence of human catalase was
also cloned into the pGBT9 vector. The results show that both
proteins bind the PTS1 receptor (Table I). Although the ob-
served binding was weak, it nevertheless represents a true
interaction because a similar degree of binding was observed
with catalase and may reflect the low affinity expected of a
transient interaction in vivo. When the 8.7-kb and 3.51-kb
ATM cDNA constructs in pAS2, both lacking the extreme C
terminus, were used with Pex5p there was no interaction. The
8.7-kb construct expresses almost full-length ATM protein (cor-
responding to amino acids 1–2934), and we have previously
used it to demonstrate an interaction between ATM and p53
(12). The 3.51-kb construct lacks 491 bp at the C terminus. In
toto, these data suggest that ATM may be imported into per-
oxisomes via the PTS1 pathway.
Reduced Extra-nuclear ATM in Peroxisome Biogenesis Dis-
order Cells—It would be predicted that, where there is a PTS1
import defect, ATM should be absent or reduced in peroxisomes
but present in the nucleus. Peroxisome biogenesis disorders
result from failure to assemble normal peroxisomes. Peroxi-
some biogenesis disorder patients can be divided into at least
10 complementation groups, reflecting the complexity of the
import process (33). We therefore performed subcellular frac-
tionation, followed by immunoblotting for ATM, on Zellweger
complementation group 4 cells (GM13267) compared with nor-
mal fibroblasts. Complementation group 4 cells contain a defect
in an ATPase (Pex6p), which is required for stability of the
receptor, Pex5p (30). It is clear that the relative amount of ATM
in the post-mitochondrial pellet fraction versus nuclear ATM in
GM13267 cells is reduced compared with that in normal cells
(Fig. 4). Immunoblotting with antibody to DNA-PK was used to
show that there was no contamination of nuclear material in
the post-mitochondrial pellet fraction (data not shown). ATM
was also found in the cytoplasm of this peroxisome biogenesis
disorder line (data not shown), similar to that observed previ-
ously for the ATM protein in the A-T cell line (AT1ABR) ex-
pressing mutant ATM protein (24).
Decreased Catalase Activity and Increased Lipid Hydroper-
oxide Levels in A-T—There have been reports in the literature
(although controversial) of defects in catalase activity in some
A-T cell lines (34). The significance of these observations re-
quired reinvestigation in view of our finding of ATM in the
peroxisome. We found significantly reduced catalase activity
(50–70% of normal) in all the A-T fibroblasts tested (Table II).
The reduction in activity does not appear to be due to reduced
protein levels because no obvious change in the amount of
catalase was detected by immunoblotting with anti-catalase
antibodies (data not shown). In addition the distribution of
catalase in A-T cells as assessed by fluorescence immunohisto-
chemistry appears normal (data not shown). A consequence of
reduced catalase activity would be increased hydrogen peroxide
levels in the cell, which would in turn be expected to result in
increased levels of lipid hydroperoxides. Lipid hydroperoxides
were therefore measured in several normal and A-T fibroblasts,
and the results are shown in Table III. It is evident that the
levels of peroxides are significantly higher than controls in all
A-T lines tested.
DISCUSSION
Our previous studies on the localization of ATM indicated
that a proportion of the protein is localized outside the nucleus
in vesicular structures (24). Using several different independ-
ent techniques and different anti-ATM antibodies, this study
has shown that ATM is present in peroxisomes. We further
demonstrated binding of the C-terminal half of ATM to Pex5p,
the receptor for proteins containing a PTS1 signal. In addition
we showed that ATM is markedly reduced in the post-mito-
FIG. 3. Presence of ATM in peroxisomes. A, fractionation of
mouse liver peroxisomes on a Nycodenz gradient showing total protein,
the distribution of catalase (peroxisomes), and succinate dehydrogenase
(SDH) (mitochondria). B, upper panel, Western blot of fractions from
the gradient using CT-1 antibody. Lane 0, nuclear extract of STO cells;
lanes1–5, gradient fractions 1–5, respectively (see Fig. 2A) ATM immu-
noreactivity (indicated by the arrow) is evident in the peak fraction (#3)
corresponding to the peak of catalase activity. Lower panel, immuno-
blotting of peroxisome gradient fractions showing absence of the highly
abundant nuclear protein, DNA-PK. Lane 0, nuclear extract from gra-
dient isolation; lanes 1–5, fractions 1–5 from a typical peroxisome
isolation, respectively.
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chondrial pellet of GM13267 cells, which have a defect in the
import of proteins into peroxisomes. The nuclear and peroxiso-
mal forms of ATM appear to be identical in as far as the C
terminus is concerned, because both are recognized by the
monoclonal anti-C-terminal peptide antibody, CT-1. The mech-
anisms that determine the distribution of ATM between the
nucleus and peroxisomes are presently unknown, and in addi-
tion there is no obvious nuclear localization signal in the pro-
tein. Determination of the exact peroxisomal targeting signal
must also await detailed site-directed mutagenesis studies. In
this regard, although catalase has been shown to bind to the
PTS1 receptor (Ref. 32 and this study), a recent report indi-
cates that the import of catalase is more complex (35). Although
we have shown that ATM also binds the PTS1 receptor, we
have not yet demonstrated that ATM is internalized in the
peroxisomal matrix. It may be bound to the peroxisome
membrane.
As pointed out by Rotman and Shiloh (36), several lines of
evidence suggest that the hypersensitivity of A-T cells to ion-
izing radiation may not result solely from defective cell cycle
checkpoints and DNA damage processing. The constitutive ac-
tivation of several IR-responsive signaling pathways in unirra-
diated A-T cells, which resembles but does not achieve the
same extent as that in irradiated control cells, indicates that
these cells are in a state of continuous oxidative stress. In
addition, red blood cells from A-T heterozygotes have been
reported to contain a lower content of sulfhydryl groups, in-
creased membrane fluidity and increased lipid peroxidation
(37). We have now demonstrated decreased levels of catalase
and increased levels of lipid hydroperoxides in several A-T cell
lines. The major mechanisms for disposal of hydrogen peroxide
are catalase and glutathione peroxidase, both of which occur in
peroxisomes as well as in the cytoplasm. The continuous state
of oxidative stress in A-T could be explained by a deficiency in
the detoxification of reactive oxygen species, and this may
result from the decreased catalase activity observed here. In-
triguingly, catalase activity in the livers of atm2/2 is not sta-
tistically different to normal (data not shown), suggesting
fundamental differences between mice and humans or differ-
ent tissues in response to lack of peroxisomal ATM. This may
be significant in terms of the much less severe neurodegen-
eration seen in atm2/2 mice (38–41) and requires further
investigation.
It should be pointed out that ATM is also present on nonper-
oxisomal vesicles co-localizing with b-adaptin (29), and ATM
binds in vitro to the neuronal homologue of b-adaptin, b-neu-
ronal adaptin-like protein. Because it has been suggested that
b-NAP plays an essential role in synaptic vesicle transport in
neuronal cells, the absence of ATM from these vesicles could
also contribute to neuronal degeneration. Indeed there is evi-
dence that defects in synaptic vesicle transport give rise to
ataxia in humans (42). It is intriguing to suggest that the
function of the noncatalase vesicles and peroxisomes may be
interrelated, in that components of the peroxisome importation
machinery (peroxins) have been localized to vesicles distinct
from mature peroxisomes (43), and the endoplasmic reticulum
plays an essential role in peroxisome biogenesis (44).
Many of the features of A-T, for example defects in cell cycle
checkpoints and aberrant meiosis, are consistent with the nu-
FIG. 4. Reduced extranuclear ATM in fibroblasts from patients
with peroxisome biogenesis disorders. Western blot of ATM in
nuclear (N) and post-mitochondrial organelle fractions (M) from
complementation group 4 cells (GM13267) and normal fibroblasts
(NFF). Equal amounts of protein (30 mg) were loaded in each lane and
verified by Ponceau S staining before immunoblotting.
TABLE I
Quantitation of the yeast two hybrid screen by liquid culture b-galactosidase assay
Plasmid co-transformations Units
4.01 kb ATM in pAS2 1Pex5p in pGAD10 1.41 6 0.09
Catalase in pGBT9 1Pex5p in pGAD10 1.69 6 0.08
pVA3a 1pTD1 (1ve control) 33 6 5
pAS2 1Pex5p (2ve control) 0.03 6 0.01b
4.01 kb ATM in pAS2 1pGAD10 No colonies
3.51 kb ATM (Nco1-Not1) in pAS2 1Pex 5p in pGAD10 No colonies
8.7 kb ATM in pAS2 1Pex 5p in pGAD10 No colonies
a pVA3 and pTD1 are positive control plasmids encoding a murine p53/GAL4 DNA-binding domain hybrid in pGBT9 and an SV40 large
T-antigen/GAL activation domain hybrid in pGAD3F, respectively.
b Only a few colonies were detected.
TABLE II
Catalase activity in normal and A-T fibroblasts
Fibroblast extracts were prepared as described under “Experimental
Procedures,” and catalase activity was measured by the decrease in
absorbance of the substrate, hydrogen peroxide, at 240 nm. The exper-
iment was performed three times, and each determination was per-
formed in triplicate. The results represent the means 6 S.D. of the
combined results. NFF, neonatal foreskin fibroblasts. PGPF and JRRF,
normal human dermal fibroblasts.
Cell type Specific activity
units/mg
Normal fibroblasts
NFF 7.78 6 2.77
PGPF 6.33 6 2.55
JRRF 8.02 6 2.79
A-T fibroblasts
AT5B/VA 2.53 6 1.39a
AT13LA 4.48 6 1.72a
GM3395 3.72 6 2.09a
GM3487A 4.48 (n 5 1)
a The value is significantly different at the p , 0.005 level from that
of normal fibroblasts.
TABLE III
Lipid hydroperoxides in fibroblasts
Lipid peroxides were measured using a kit as described under “Ex-
perimental Procedures.” This experiment was performed three times
with similar results. The values shown are from one experiment and
represent the means 6 S.D. of triplicate determinations. NFF, neonatal
foreskin fibroblasts.
Fibroblasts Protein
nmol/mg
Normal
NFF 1.20 6 0.006
PGPF 1.17 6 0.006
JRRF 1.19 6 0.014
A-T
AT5B/VA 1.74 6 0.036a
AT13LA-SV 1.77 6 0.030a
GM3395 1.71 6 0.039a
GM3984A 1.67 6 0.027a
a The value is significantly different at the p , 0.001 level from
normal fibroblasts.
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clear localization of ATM. However, an explanation for the
basis of the most debilitating and characteristic symptoms of
the disease, the neurological dysfunction, has so far been elu-
sive. Some peroxisome biogenesis disorders show similarity
with A-T, for example, ataxia that occurs in infantile Refsum’s
disease (45) and demyelination, which occurs in X-linked adre-
noleukodystropy (46). ATM is found predominantly outside the
nucleus in Purkinje cells (47).2 Thus in noncycling cells the
primary function of ATM would be in the maintenance of cel-
lular homeostasis. In summary, we have demonstrated that
ATM is associated with peroxisomes, which provides a new
direction for investigating the role of ATM.
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